146
Participants
Start Date
January 31, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Tasquinimod
A patient initially received a 0.25 mg/day dose which was then titrated through 0.5 mg/day (from Day 15) to a maximum of 1 mg/day (from Day 29). If tolerability issues arose at 0.5 or 1 mg/day, patients had their dose reduced to 0.25 or 0.5 mg/day, respectively.
Placebo
Placebo capsules were identical to tasquinimod capsules in appearance and excipients but excluded the active compound (tasquinimod).
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
West China Hospital Sichuan University, Chengdu
Beijing Chao-Yang Hospital Capital Medical University, Beijing
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Beijing Friendship Hospital Capital Medical University, Beijing
Peking University Third Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Beijing Hospital of Ministry of Health, Beijing
Ruijin Hospital Shanghai Jiaotong University of Medicine, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Huadong Hospital Fudan University, Shanghai
Huashan Hospital Fudan University, Shanghai
Shanghai Tenth People's Hospital, Shanghai
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Jiangsu Cancer Hospital, Nanjing
The Second Affiliated Hospital of Soochow University, Suzhou
Tianjin Medical University Cancer Institute and Hospital, Tianjin
The First Affiliated Hospital College of Medicine Zhujiang University, Hangzhou
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Southwest Hospital (the First Affiliated Hospital of Third Military Medical University PLA), Chongqing
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
Sun Yat-sen University Cancer Center, Guangzhou
Guangshou First People's Hospital, Guangzhou
Sichuan Academy of Sichuan Medical Sciences & Sichuan Provincial People's Hospital, Chengdu
General Hospital Chengdu Military Region of PLA, Chengdu
Chungbuk National University Hospital, Cheongju-si
Chonnam National University Hospital, Gwangju
Gangnam Severance Hospital, Seoul
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Ipsen
INDUSTRY